Cargando…
Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome
Azacitidine is a first-in-class demethylating agent, and it is widely used globally as a first-line treatment for higher-risk myelodysplastic syndrome (MDS). Here, we report the case of a patient with MDS who suffered from a rare adverse event, an acute lung injury (ALI), which was suspected to have...
Autores principales: | Makita, Shinichi, Munakata, Wataru, Watabe, Daisuke, Maeshima, Akiko Miyagi, Taniguchi, Hirokazu, Toyoda, Kosuke, Yamauchi, Nobuhiko, Fukuhara, Suguru, Maruyama, Dai, Kobayashi, Yukio, Tobinai, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536648/ https://www.ncbi.nlm.nih.gov/pubmed/28415946 http://dx.doi.org/10.1177/0300060517698331 |
Ejemplares similares
-
The role of local radiotherapy following rituximab‐containing chemotherapy in patients with transformed indolent B‐cell lymphoma
por: Nozaki, Kenji, et al.
Publicado: (2020) -
Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2020) -
Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016) -
Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021) -
Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors
por: Suzuki, Tomotaka, et al.
Publicado: (2020)